Literature DB >> 26180658

Carcinoma en Cuirasse from Recurrent Breast Cancer seen on FDG-PET/CT.

Aung Zaw Win1, Carina Mari Aparici2.   

Abstract

Our patient was a 36-year-old female diagnosed with Grade II ER+/PR-/Her-2 - ductal carcinoma in situ (DCIS) in the left breast. She underwent left lumpectomy and received treatment with tamoxifen and radiotherapy. Three years later, she presented with multiple diffused skin nodules on the chest and upper left arm. 18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) exam showed widespread metastasis in the chest, upper left arm, left axillary lymph nodes, and left suprascapular muscle. FDG-PET/CT imaging of breast carcinoma en cuirasse is very rare. FDG-PET/CT is useful in detecting recurrent breast cancer.

Entities:  

Keywords:  Breast cancer; FDG-PET/CT; carcinoma en cuirasse; metastasis

Year:  2015        PMID: 26180658      PMCID: PMC4490574          DOI: 10.4103/2156-7514.159456

Source DB:  PubMed          Journal:  J Clin Imaging Sci        ISSN: 2156-5597


INTRODUCTION

The major sites of breast cancer metastasis in decreasing prevalence are the lungs, bone, liver, adrenal, and brain.[1] Cutaneous metastasis from internal malignancies is rare with a reported incidence between 0.7% and 9% and it may be a sign of cancer recurrence.[2] Skin metastases from breast cancer have many forms: Telangiectatic carcinomas, erysipeloid carcinomas, “en cuirasse” carcinomas, alopecia neoplastica, and a zosteriform type.[3] Carcinoma en cuirasse is very rare and occurs in only 3% of cutaneous metastasis cases.[3] Carcinoma en cuirasse is caused by lymphatic spread. Carcinoma en cuirasse is described as small, multiple erythematous nodules which can enlarge and coalesce to form plaques.[3]18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) can scan the whole body for metastases in one exam, whereas serial CTs are required to accomplish the same task.

CASE REPORT

The patient was a 36-year-old female who presented with pain under the left arm. The ultrasound revealed a 2.5 cm irregular mass in the upper outer quadrant of the left breast and a subsequent mammogram showed an asymmetric density in the same region. Left lumpectomy removed a 4.9 cm mass and pathology confirmed it as ER+/PR−/Her-2– intermediate-grade ductal carcinoma in situ (DCIS) with positive margins. Left breast re-excision was done and there was no evidence of residual disease. Sentinel lymph node biopsy was negative and FDG-PET/CT showed only postsurgical changes [Figure 1]. She was then treated with tamoxifen and radiotherapy. About 3 years later, the patient presented with multiple skin nodules on the chest and upper left arm. FDG-PET/CT revealed extensive metastatic disease involving left axillary lymph nodes, left suprascapular muscle, chest, and left upper arm [Figure 2a–c]. Biopsies were done on the chest, left suprascapular muscle, and left axillary lymph nodes and they showed poorly differentiated ER+/PR−/Her-2adenocarcinoma. She was experiencing progressive pain and weakness in the left upper extremity.
Figure 1

36-year-old female presented with pain under the left arm and was diagnosed with intermediate-grade DCIS. FDG-PET/CT Maximum Intensity Projection (MIP) image shows only postsurgical changes with no evidence of residual or metastatic disease.

Figure 2

36-year-old female presented with pain under the left arm and multiple skin lesions 3 years after surgery for DCIS. (a) FDG-PET/CT Maximum Intensity Projection (MIP) image shows cutaneous metastases (arrows) on the chest and left upper extremity. (b) PET and (c) hybrid PET/CT images, axial view show breast cancer infiltration in the left suprascapular muscle and left axillary lymph nodes (arrows) (SUV 7.09).

36-year-old female presented with pain under the left arm and was diagnosed with intermediate-grade DCIS. FDG-PET/CT Maximum Intensity Projection (MIP) image shows only postsurgical changes with no evidence of residual or metastatic disease. 36-year-old female presented with pain under the left arm and multiple skin lesions 3 years after surgery for DCIS. (a) FDG-PET/CT Maximum Intensity Projection (MIP) image shows cutaneous metastases (arrows) on the chest and left upper extremity. (b) PET and (c) hybrid PET/CT images, axial view show breast cancer infiltration in the left suprascapular muscle and left axillary lymph nodes (arrows) (SUV 7.09).

DISCUSSION

FDG-PET imaging of breast carcinoma en cuirasse is very rare. This is the first case to show FDG-PET/CT images of suprascapular muscle metastasis from breast cancer. Skeletal muscle is an unusual site for breast cancer metastasis and it occurs by the hematogenous route.[4] The chest is the most common site of cutaneous metastasis.[1] Abdomen, back, and upper extremities are less common sites of skin metastasis.[5] In our patient, cutaneous metastasis occurred in the chest and left upper extremity. Our patient was first diagnosed with breast cancer at the age of 36 and breast cancer in this age group is very rare.[6] Young age (less than 40 years) is an independent predictor of tumor recurrence following breast-conserving surgery.[6] Our patient had lumpectomy in the left breast and the cancer recurred 3 years after the surgery. According to the biopsy report, she had ER+/PR−/Her-2ductal carcinoma. Interestingly, younger patients with ER +ve tumors have a poorer disease-free survival than those with ER −ve tumors.[7] Ultrasound (US) and CT mostly focus on the size of the lymph nodes, while FDG-PET/CT looks at the biological activity of tumors. Intramuscular hot spots on PET/CT scans should be considered as a sign of metastasis, even in the absence of abnormalities on CT scans.[8] It is difficult to detect skeletal muscle metastasis with the generally used CT scans.[8] In the present case, the extent of breast cancer recurrence was clearly demonstrated by the PET/CT exam. FDG-PET/CT has 93% sensitivity and 100% specificity in detecting breast cancer recurrence.[4] Aukema et al., even suggested that PET/CT can replace conventional imaging in patients with breast cancer recurrence.[9]

CONCLUSION

PET scanning can reveal unexpected sites of metastasis. This case has demonstrated that FDG-PET/CT is useful in demonstrating the extent of breast cancer recurrence. Skin lesions in a patient with history of breast cancer should raise the suspicion of cancer recurrence.
  9 in total

1.  Metastatic breast carcinoma mimicking a sebaceous gland neoplasm: a case report.

Authors:  Cornelia Sl Müller; Rebecca Körner; Ferenc Z Takacs; Erich F Solomayer; Thomas Vogt; Claudia Pfoehler
Journal:  J Med Case Rep       Date:  2011-09-02

2.  Metastatic cutaneous breast carcinoma: A case report and review of the literature.

Authors:  Guillermina Nava; Kenneth Greer; James Patterson; Kant Y Lin
Journal:  Can J Plast Surg       Date:  2009

3.  The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.

Authors:  T S Aukema; E J Th Rutgers; W V Vogel; H J Teertstra; H S Oldenburg; M T F D Vrancken Peeters; J Wesseling; N S Russell; R A Valdés Olmos
Journal:  Eur J Surg Oncol       Date:  2009-12-03       Impact factor: 4.424

4.  Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.

Authors:  Albert Dirisamer; Benjamin S Halpern; Daniel Flöry; Florian Wolf; Mohsen Beheshti; Marius E Mayerhoefer; Werner Langsteger
Journal:  Eur J Radiol       Date:  2009-02-01       Impact factor: 3.528

5.  Skeletal muscle metastases from breast cancer: two case reports.

Authors:  Young Woo Kim; Kyung Jin Seo; Su Lim Lee; Ki Wook Kwon; Joon Hur; Ho Jung An; Yoon Ho Ko; Jeong Soo Kim; Hye Sung Won
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

6.  Cutaneous metastases from carcinoma breast: the common and the rare.

Authors:  Smitha Prabhu; Sathish B Pai; Sripathi Handattu; Mohan H Kudur; Vani Vasanth
Journal:  Indian J Dermatol Venereol Leprol       Date:  2009 Sep-Oct       Impact factor: 2.545

7.  Trends in surgery for screen-detected and interval breast cancers in a national screening programme.

Authors:  J Nederend; L E M Duijm; M W J Louwman; R M H Roumen; F H Jansen; A C Voogd
Journal:  Br J Surg       Date:  2014-05-15       Impact factor: 6.939

8.  Predictive value of pathological and immunohistochemical parameters for axillary lymph node metastasis in breast carcinoma.

Authors:  Sibel Yenidunya; Reyhan Bayrak; Hacer Haltas
Journal:  Diagn Pathol       Date:  2011-03-13       Impact factor: 2.644

9.  Cutaneous metastases of breast carcinoma: a case report.

Authors:  Sergio Vano-Galvan; Paula Moreno-Martin; Irene Salguero; Pedro Jaen
Journal:  Cases J       Date:  2009-01-21
  9 in total
  2 in total

1.  Carcinoma en cuirasse.

Authors:  Ashlee L Culver; David M Metter; John E Pippen
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-03-26

2.  Rapid progression of carcinoma en cuirasse breast dermal metastases on 18F-fludeoxyglucose positron emission tomography-computed tomography.

Authors:  Colin Raymond Young; Mallini Harigopal; Darko Pucar
Journal:  World J Nucl Med       Date:  2019-11-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.